The Cost-Effectiveness of Cognitive Behavioral Therapy Versus Second-Generation Antidepressants for Initial Treatment of Major Depressive Disorder in the United States: A Decision Analytic Model.

Clicks: 492
ID: 63675
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 62 articles by views in annals of internal medicine

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Most guidelines for major depressive disorder recommend initial treatment with either a second-generation antidepressant (SGA) or cognitive behavioral therapy (CBT). Although most trials suggest that these treatments have similar efficacy, their health economic implications are uncertain.To quantify the cost-effectiveness of CBT versus SGA for initial treatment of depression.Decision analytic model.Relative effectiveness data from a meta-analysis of randomized controlled trials; additional clinical and economic data from other publications.Adults with newly diagnosed major depressive disorder in the United States.1 to 5 years.Health care sector and societal.Initial treatment with either an SGA or group and individual CBT.Costs in 2014 U.S. dollars, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios.In model projections, CBT produced higher QALYs (3 days more at 1 year and 20 days more at 5 years) with higher costs at 1 year (health care sector, $900; societal, $1500) but lower costs at 5 years (health care sector, -$1800; societal, -$2500).In probabilistic sensitivity analyses, SGA had a 64% to 77% likelihood of having an incremental cost-effectiveness ratio of $100 000 or less per QALY at 1 year; CBT had a 73% to 77% likelihood at 5 years. Uncertainty in the relative risk for relapse of depression contributed the most to overall uncertainty in the optimal treatment.Long-term trials comparing CBT and SGA are lacking.Neither SGAs nor CBT provides consistently superior cost-effectiveness relative to the other. Given many patients' preference for psychotherapy over pharmacotherapy, increasing patient access to CBT may be warranted.Department of Veterans Affairs, National Institute of Mental Health.
Reference Key
ross2019theannals Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ross, Eric L;Vijan, Sandeep;Miller, Erin M;Valenstein, Marcia;Zivin, Kara;
Journal annals of internal medicine
Year 2019
DOI
10.7326/M18-1480
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.